Roche Holding AG (SWX:ROP)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 259.40B +23.0% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | 16.04 +55.6% |
| Shares Out | 795.62M |
| PE Ratio | 20.28 |
| Forward PE | 15.80 |
| Dividend | 9.80 (3.03%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 227,478 |
| Open | 324.70 |
| Previous Close | 325.30 |
| Day's Range | 324.50 - 328.60 |
| 52-Week Range | 243.90 - 374.90 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 360.76 (+10.19%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ROP stock is "Buy." The 12-month stock price target is CHF 360.76, which is an increase of 10.19% from the latest price.
News
OraSure announces FDA clearance of Colli-Pee Dx Urine Collection Kit
OraSure (OSUR) announced FDA clearance of its Colli-Pee Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche’s (RHHBY) tests for Chlamydia trachomatis, Neisseria gonorrhoea...
Genentech granted priority review for Tecentriq Hybreza combination
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application, or sBLA, filing for adjuvant Tecentriq and Tecentriq Hybreza in comb...
Roche announces EU IVDR approval of several Ventana label expansions
Roche (RHHBY) announced the European Union In Vitro Diagnostic Regulation, or IVDR, approval of several label expansions for the Ventana MMR RxDx Panel, an immunohistochemistry companion diagnostic te...
FDA Grants Priority Review for Genentech's Tecentriq for a Certain Type of Stage III Colon Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies By evaluating a panel of MM...
FDA grants Priority Review for Roche's Tecentriq for a certain type of stage III colon cancer
Basel, 11 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) f...
Roche sticks to German investment after Eli Lilly cuts
The Swiss pharmaceutical and diagnostics giant Roche said it is sticking to its planned investments in Germany, unlike some of its competitors that have scaled back spending in the country.
Roche Holding AG Transcript: Study update
Phase II results show enicepatide achieved up to 22.7% weight loss at 48 weeks, with strong glycemic improvements and favorable tolerability. Petrelintide demonstrated up to 10.7% weight loss with a placebo-like safety profile, supporting its use for moderate weight loss. Both agents advance to phase III, with combination studies planned.
Roche Holding AG Slides: Study update
Roche Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.
Nurix Therapeutics Stock (NRIX) Soars 40% After $2.3B Blood Cancer Deal with Roche
Shares in biopharmaceutical company Nurix Therapeutics ($NRIX) soared nearly 40% in pre-market trading after sealing a $2.3 billion blood cancer deal with Swiss pharmaceutical giant Roche ($RHHBY). Bl...
Nurix Therapeutics teams with Roche to develop, commercialize bexobrutideg
Nurix Therapeutics (NRIX) announced a global collaboration with Roche (RHHBY) to develop and commercialize bexobrutideg, an oral degrader of Bruton’s tyrosine kinase, or BTK. The partnership brings to...
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clini...
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche's oncology pipeline and offers potential indica...
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity drug, with more than a quarter of those who received the highest dose a...
Zealand touts promising tolerability data for obesity drug in mid-stage study
Zealand Pharma said on Friday its experimental obesity drug, co-developed with Swiss partner Roche , showed encouraging tolerability in a mid-stage trial, bolstering its push to take on market leader...
Roche reports developing PCR test for Ebola within six days
Roche (RHHBY) announced that it developed a Research Use Only molecular PCR test, via its subsidiary TIB MOLBIOL, for use on the LightCycler 480 I & II Systems, LightCycler PRO…
Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
New Roche test targeting detection of Bundibugyo virus supports efforts to address critical need during ongoing outbreaks 1 Roche's unique outbreak response capabilities enabled rapid development of t...
Roche chairman likens US tariff policy to 'blackmail'
The chairman of Swiss pharmaceutical giant Roche hit out at U.S. tariff policies on Thursday, likening them to "blackmail", and said protectionism by the United States and China was the firm's bigge...
Ideaya Biosciences announces IDE892 collaboration with Roche
Ideaya Biosciences (IDYA) announced it has entered into a clinical collaboration with Roche (RHHBY) to evaluate the efficacy and safety of IDE892 in combination with Roche’s RG6505, a pan-RAS inhibito...
Roche Holding AG Transcript: Investor update
Oncology and hematology delivered strong Q1 growth, led by breast and lung cancer therapies and pipeline innovation. Giredestrant showed significant efficacy in adjuvant breast cancer, with multiple ongoing trials to expand its use. Divarasib and other RAS-targeted therapies are advancing, with a focus on combination strategies and new modalities.
Roche Holding AG Slides: Investor update
Roche Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Genentech announces FDA acceptance of giredestrant NDA under Priority Review
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s new drug application, or NDA, under Priority Review for giredestrant, an investigational oral selective estrogen...